Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Mesothelin inhibitor

DRUG CLASS:

Mesothelin inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

MSLN positive	Mesothelioma	MSLN positive	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Lung Cancer	MSLN expression	Lung Cancer	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Ovarian Cancer	MSLN expression	Ovarian Cancer	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Mesothelioma	MSLN expression	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN overexpression	Ovarian Cancer	MSLN overexpression	Ovarian Cancer	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3
MSLN overexpression	Malignant Pleural Mesothelioma	MSLN overexpression	Malignant Pleural Mesothelioma	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3
MSLN overexpression + TP53 mutation	Ovarian Cancer	MSLN overexpression + TP53 mutation	Ovarian Cancer	TC-210 Sensitive: C4 – Case Studies TC-210 Sensitive : C4	TC-210 Sensitive: C4 – Case Studies TC-210 Sensitive : C4
MSLN overexpression	Solid Tumor	MSLN overexpression	Solid Tumor	HK013 Sensitive: D – Preclinical HK013 Sensitive : D	HK013 Sensitive: D – Preclinical HK013 Sensitive : D
MSLN expression	Solid Tumor	MSLN expression	Solid Tumor	CT-95 Sensitive: D – Preclinical CT-95 Sensitive : D	CT-95 Sensitive: D – Preclinical CT-95 Sensitive : D